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In contrast to their higher incidence of radiation-induced solid tumors, patients with bilateral 26 
retinoblastoma (RB) have a low risk of developing therapy-related hematological malignancies. We 27 
present the first case of a patient with bilateral RB to develop chronic myeloid leukemia (CML) 15 28 
years after multimodality therapy, comprising systemic chemotherapy and external beam radiation 29 
to the orbits. We discuss the possible etiology of therapy-related CML in long-term survivors with 30 





The overall survival rate of patients with intraocular retinoblastoma (RB) exceeds 95%.1 In addition 34 
to conventional treatment modalities, such as enucleation and external beam radiation, systemic 35 
chemotherapy, focal laser therapy, cryotherapy, brachytherapy, and the recently established 36 
selective ophthalmic arterial and intravitreal injection have been performed for ocular salvage and 37 
vision preservation.2–4 Since the majority of patients with RB now survive into adulthood, late 38 
adverse effects have become a focus for clinical and research areas. Therapy-related malignancy is 39 
one of the most severe late adverse effects.1 Patients with bilateral RB, who invariably have 40 
germline RB gene mutation, are at significant risk of therapy-related malignancy.5 In contrast to 41 
their higher incidence of radiation-induced solid tumors, patients with bilateral RB have a low risk 42 
of developing therapy-related hematological malignancies,5–8 and the etiologies of therapy-related 43 
hematological malignancies in these patients remain largely unknown. 44 
 In the present study, we report a rare case who developed chronic myeloid leukemia 45 
(CML) 15 years after the treatment for bilateral RB. 46 
 47 
RESULTS 48 
A 4-month-old male infant with bilateral RB was successfully treated by enucleation of the right eye, 49 
41.8 Gy of external beam radiation to the orbits, 6 months of chemotherapy with vincristine and 50 
cyclophosphamide, and cryotherapy and photocoagulation for the left eye. He had no family history 51 
of malignancy. He experienced local relapse with vitreous seeding four times thereafter, during 52 
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which he received multiple rounds of systemic chemotherapy, comprising etoposide, 53 
cyclophosphamide, and pirarubicin, in combination with intra-arterial and intravitreal injections of 54 
melphalan, cryotherapy, and brachytherapy for the left eye. He finally underwent enucleation of 55 
the left eye at the age of 10 years, which resulted in long-term remission. The cumulative doses of 56 
chemotherapy drugs were as follows: etoposide, 1000 mg/m2; cyclophosphamide, 19.6 g/m2; 57 
pirarubicin, 310 mg/m2; cisplatin, 90 mg/m2; carboplatin, 750 mg/m2; and vincristine, 51 mg/m2.  58 
 At 25 years old, laboratory studies during annual follow-up revealed a white blood count 59 
count of 32.3 ×109/L (myelocytes, 11%; metamyelocytes, 2%; neutrophils, 69%; basophils, 5%; 60 
monocytes, 4%; lymphocytes, 9%), hemoglobin of 14.0 g/dL, and a platelet count of 218 ×109/L, 61 
although he did not have any clinical symptoms. Biochemical examination revealed marked 62 
elevation of lactate dehydrogenase (711 U/L) and uric acid (7.3 mg/dL). Bone marrow aspiration 63 
revealed distinct hypercellularity and a markedly increased myeloid:erythroid ratio (8.43) without 64 
increased blasts. Karyotype analysis demonstrated a chromosome translocation, 46, XY, 65 
t(9;22)(q34;q11.2), in all 20 bone marrow cells analyzed. Detection of the major BCR-ABL fusion 66 
gene transcripts (2.9 × 106 copies/μgRNA) on quantitative polymerase chain reaction led to a 67 
diagnosis of CML in chronic phase. Treatment with dasatinib (100 mg/day) normalized the white 68 
blood count within 1 month. Bone marrow aspiration after 3 months revealed normocellular marrow, 69 
and the quantitative polymerase chain reaction revealed a 4.2 log reduction of the major BCR-ABL 70 
fusion gene transcripts (1.7 × 102 copies/μgRNA). Fluorescence in situ hybridization analysis for 71 
the BCR-ABL fusion gene and cytogenetic karyotyping results were normal, achieving complete 72 
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cytogenetic response and an optimal response, according to the European LeukemiaNet 73 
recommendations.9  74 
 75 
DISCUSSION 76 
Patients with bilateral RB have a high risk of developing secondary malignancies, with a 77 
cumulative incidence of approximately 30% at 40–50 years from diagnosis.6, 8 About half of 78 
secondary malignancies are bone and soft tissue sarcomas, while only 0.5–0.6% are hematological 79 
malignancies (Table 1).6–8 Although various types of leukemia and lymphoma have been observed 80 
as secondary hematological malignances in patients treated for RB, there are no reports of 81 
secondary CML. Moreover, etoposide or alkylator-containig chemotherapy, does not increase the 82 
risk of secondary CML in the general population.10 Overall, there is no clear reason to assume an 83 
association between chemotherapy and development of CML in the present case.  84 
Howard et al. identified 164 patients with secondary CML in 376,835 long-term survivors 85 
with breast cancer, representing an excess absolute risk of 2.06 per 100,000 person-years.11 86 
Dose-dependent increased risk of radiation-related CML has also been demonstrated in patients 87 
with cervical cancer and ankylosing spondylitis, and in Japanese atomic bomb survivors.12 The 88 
frequency of secondary CML has decreased over time, possibly due to the recent progress in 89 
radiation therapy techniques that allow minimal exposure of the bone marrow to radiation.11 90 
Secondary CML is an extremely rare event in patients with RB, considering that approximately 91 
80% of patients received radiation therapy,6, 8 which might be explained by the limited field of 92 
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radiation to the periorbital bone marrow. Thus, CML in the present case is likely associated with 93 
radiation therapy, although the possibility of de novo CML cannot be completely excluded.  94 
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